Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Baxter and Chatham Partner to Develop Hemophilia Treatments
 

In June, Baxter International Inc., announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B using Chatham’s gene therapy technology.

 

As part of the agreement, Baxter will use Chatham’s Biological Nano ParticlesTM (BNP), a recombinant adeno-associated virus-(rAAV) based gene therapy technology, to develop therapies for hemophilia B. Baxter has obtained global rights for the marketing and commercialization of the new treatment. While earlier clinical studies have shown the potential benefits of such a therapy, Baxter and Chatham intend to further investigate the experimental therapy through US-based clinical trials.

 

Source: RTTnews.com, June 5, 2012